The monopoly is over. The question is whether the annuity ever was one.
For twenty years Intuitive Surgical had no credible competitor in soft-tissue robotics. In eight months it acquired two — Medtronic's Hugo in December, J&J's Ottava in July. Meanwhile revenue still grew 19% and non-GAAP earnings 28%, and the stock lost a third of its value. Five analyst lenses, three scenarios, four horizons.
Gray line = ISRG's actual monthly closes from mid-2024 into today — a run from $444.85 (Jun ’24) to a $573.48 monthly-close peak in Nov ’25, then seven consecutive down months to a $353.33 July close and a $328.57 intraday low, before August's bounce to $378.81. Colored paths right of the TODAY crosshair are synthesized scenario midpoints, weighted base 50% · bull 25% · bear 25%. Mid-year marks. The clay circle is Wall Street's 12-month consensus of $478.01 (range $324–$685, 33 analysts, S&P Global, Aug 2026).
Re-weight the scenarios
Those probabilities are this desk's judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of every scenario card update live.
Five analyst lenses, five different answers
Each lens below was run independently, with the same ground-truth data and no sight of the others, so the disagreement is real rather than staged. Targets span $311 to $500 — a 61% spread on identical facts.
The Utilization Flywheel
Procedures (+16%) are out-running the installed base (+12%) — utilization per system is rising, and ~85% of revenue repeats without a new capital sale. 246 of 468 placements were da Vinci 5 against a ~7-year upgrade cadence, and August's cardiac clearance takes ~17,000 procedures toward a ~160,000/yr addressable pool. Non-GAAP EPS +28% on revenue +19% is nine points of operating leverage already printing.
The Cash Counter
FCF more than doubled to $3.22B as capex rolled from $1,111M (FY24) to $484M TTM — but capex intensity fell from 13.3% of revenue to 4.4%, which is a trough, not a run-rate. Normalize it and the yield is ~2.2%. Net cash of ~$8.5B ($24.43/share) funds a price war; it does not set a floor. At 39.9× EV/FCF you are still underwriting flawless compounding.
The Thesis-Killer
U.S. procedures slowed +14% → +12% on causes that are structural, not transitory: GLP-1 penetration is still climbing and ACA subsidy expiry is a multi-year coverage drag. Guidance was reaffirmed, not raised — H2 must decelerate. China is the preview of an open market: domestic brands took ~48% of 2025 unit procurement and average system prices fell ~25% in H1’26. The 66–67% gross margin was set with nobody bidding on the other side.
Wall Into Toll Road
Ottava and Hugo breach the placement monopoly, not the procedure monopoly. A hospital that buys Ottava does not un-buy da Vinci — it becomes a two-platform hospital, and the credentialed surgeons stay. Erosion runs in sequence: system ASP in greenfield and international first, incremental placement share second, instrument pricing last and slowest. Instruments (+18% on $1.73B/qtr) are the profit pool, and they are furthest from the fire.
Cheap, But Still Falling
Seven consecutive down months (Jan–Jul ’26), a death cross confirmed in March, price 18.9% below its 12-month moving average of $466.85. The +15.3% bounce off $328.57 sits squarely in the bear-rally band and has not reclaimed June's $397.68 close. Valuation says bottom-decile — 33.5× forward against a 5-year average near 69×; the tape says not yet. Beta 1.46 with zero debt is pure duration, and duration unwinds slowly.
Sell-side 12-month price targets
Bars sorted low to high, colored by rating; the dashed line is today's $378.81. Note the shape of the disagreement — one desk below the price, one at nearly double it.
Named targets are dated actions from July–August 2026: Oppenheimer upgraded to Outperform at $500 (Aug 12); HSBC downgraded to Hold at $391 (Jul 30); JPMorgan, Stifel and Citigroup all cut targets on Jul 17, the day after Q2. The unnamed endpoints are the extremes of the S&P Global range ($324 low, $685 high) — the firms behind them are not disclosed in the source. Rating distribution: 16 Strong Buy · 7 Buy · 9 Hold · 1 Strong Sell. MarketBeat's tally of 31 analysts puts the consensus higher at $508.68, so the true consensus sits somewhere in the $478–$509 band; this report uses the S&P Global figure as the primary.
Where the cone leads
Synthesized scenario midpoints, dated mid-year, shown against today's $378.81. Every number below is an EPS estimate times an exit multiple — the math is in the drawers underneath. These are illustrative frameworks, not forecasts; real outcomes can and do fall outside the cone.
1 Year
Mid-20272 Years
Mid-20283 Years
Mid-20295 Years
Mid-2031▸ Bull case (25%) — show the assumptions & math
▸ Base case (50%) — show the assumptions & math
▸ Bear case (25%) — show the assumptions & math
▸ How the probability weighting works
Revenue, capex, free cash flow & debt
The single most underrated chart in this report. Capex peaked in 2024 and halved; free cash flow more than tripled behind it — and the debt bar is barely visible at all.
The bull and bear cases both live in the gap between the clay bar and the olive one. Intuitive spent heavily on manufacturing capacity in 2023–24 (capex $1.06B then $1.11B, ~13% of revenue), then stopped — FY25 capex was $540M and the trailing-twelve-month figure through June 2026 is $484M, about 4.4% of revenue. Operating cash flow rose to $3.71B over the same stretch, so free cash flow went $750M → $1,304M → $2,491M → $3,223M TTM. The value lens's caution is that 4.4% is a trough, not a run-rate; normalize capex toward 7% of revenue and FY26 free cash flow is nearer $2.9B. Total debt (slate) is a rounding error — $171M at FY25 against $8.63B of cash and investments, so the $3.96B of trailing buybacks is funded entirely from cash. FY2026E revenue is the $11.77B analyst consensus; FY2026E capex and FCF are this desk's estimates extrapolated from the TTM run-rate and are not company guidance.
The EPS ladder underneath every target
No price target here is a guess — each is one of these bars times an exit multiple. This is the ladder.
Read the basis change carefully. Gray bars are reported GAAP diluted EPS: $3.65 (FY22) → $5.03 → $6.42 → $7.87 (FY25). Olive bars are non-GAAP estimates — FY2026E is the $10.79 analyst consensus, FY2027–31E is this desk's base-case ladder (+17% / +15% / +14% / +13% / +13%). The two measures differ mainly by stock-based compensation: FY25 was $7.87 GAAP versus $8.93 non-GAAP, so roughly $1.06 of the visible step from 2025 to 2026 is the change in basis rather than growth. Trailing GAAP EPS through June 2026 was $8.72. Base case: $21.13 of FY31E non-GAAP EPS × a 30× exit multiple ≈ the $634 five-year base-case price.
The business is still compounding
Q2 FY2026, year-over-year. Read these against a stock that has fallen 37% from its high — and read the top bar against all the others.
Ten metrics, nine of them positive. Total revenue +19%, instruments and accessories +18%, non-GAAP EPS +28%, with SP (+61%), Ion procedures (+36%) and the Ion installed base (+21%) compounding far faster off small bases (clay). The single terracotta bar is the one the bears point at: U.S. bariatric procedure volumes fell by a high-single-digit percentage as GLP-1 drugs displaced surgery — and the U.S. da Vinci line, at +12%, is the slowest growth on the board and decelerating from +14% in Q1. That is the whole debate in one chart: the frontier is fine, the core is fine, and the marginal U.S. case is not.
Bull vs. Bear
The entire valuation argument compresses into one disagreement: does an installed base of 11,710 systems and two decades of surgeon training constitute a moat, or merely a head start?
▲ THE BULL CASE
- Utilization is rising, not just the fleet. Combined da Vinci and Ion procedures grew 16% against an installed base up 12% — each system is doing more work, and ~85% of revenue recurs without a new capital sale.
- Operating leverage is already visible. Q2 non-GAAP EPS $2.80, +28%, on revenue +19% — nine points of leverage — with FY26 opex guided to grow 11–13%, below procedure growth of 13.5–15.5%.
- The cash engine inflected. Capex halved from $1,111M (FY24) to $484M TTM while operating cash flow rose to $3,706M; free cash flow went from $750M in FY23 to $3,223M trailing, funding $3.96B of buybacks with zero debt.
- Cardiac is a genuinely new market. August's da Vinci 5 clearance moves from ~17,000 cardiac procedures performed globally on legacy systems in 2025 toward an estimated ~160,000/yr addressable in the cleared markets.
- Competitors are cleared for a sliver. Ottava covers 10 general-surgery procedures; Hugo is U.S. urology-only with general and gynecologic 510(k)s only filed on June 3, 2026. J.P. Morgan expects "very modest/immaterial" share loss; Stifel notes the training burden.
- The multiple already reset. 33.5× forward against a five-year average near 69×; the de-rating happened while earnings grew 28%. Consensus still sits 26% above the price.
▼ THE BEAR CASE
- The U.S. is decelerating on structural causes. +14% (Q1) → +12% (Q2), blamed on ACA subsidy expiry and GLP-1 — neither of which reverses next quarter. U.S. bariatric volumes are already down high-single-digits.
- Guidance was reaffirmed, not raised. Management is "targeting the midpoint" of 13.5–15.5% against roughly 15% in the first half, which requires the second half to slow. The stock fell 12–14% on July 17 on that alone.
- Pricing power has never actually been tested. 66–67% gross margins were set in a market with no other bidder. China shows what an open market does: domestic brands took roughly 48% of 2025 unit procurement and average system prices fell about 25% in H1 2026.
- Half the record placements are cannibalization. ~50% of U.S. da Vinci 5 placements were trade-ins; the installed base grew 12% while placements grew 18%.
- The margin print was flattered. Q2's 70.0% non-GAAP gross margin included a one-time $36M IEPA tariff refund, against roughly 1.0 point of tariff drag embedded in the 68–69% full-year guide.
- Cheap is relative. Even after a 37% drawdown: 43× trailing, 33.5× forward, 30.8× EV/EBITDA, ~40× EV/FCF, a 2.41% FCF yield and a PEG of 2.13. A de-rated ISRG is still an expensive stock.
Risk map — likelihood × impact
Where each risk sits, not just how large it is, over a three-to-five year horizon. Grid labels are shortened; the cards beneath name each risk in full. The hot upper-right corner is the one that decides the stock; note that the competitive risks everyone talks about sit one row down.
- Tariff & input costs
- GLP-1 bariatric erosion
- U.S. growth resets lower
- FX & payer timing
- China price erosion
- Share loss to rivals
- CEO transition
- dV5 recall event
- Tool price war
- Safety action
U.S. procedures reset to high-single-digits
What breaks: procedures are the annuity — instruments and service both bill per case. Low-teens is what the whole model and every target on this page assume.
Placement share loss to Ottava / Hugo
What breaks: Intuitive stops winning the marginal operating room. System ASP compresses first in greenfield, ASC and international accounts where no surgeon is yet credentialed.
Instrument pricing repriced by a bundled rival
What breaks: the actual profit pool. If Medtronic bundles Hugo consumables across its surgical portfolio, the $1.73B-a-quarter razor-blade line becomes a negotiated price rather than a posted one.
Class-wide safety or regulatory action
What breaks: a serious adverse-event cluster or FDA action against robotic soft-tissue surgery as a category would hit the installed base, not just new sales — low odds, but it reprices everything overnight.
GLP-1 bariatric erosion
What breaks: a whole procedure category quietly leaves the operating room. U.S. bariatric volumes are already down high-single-digits and GLP-1 penetration is still climbing.
China share & price erosion
What breaks: the template. Domestic competitors plus national pricing pressure show what an open, tendered market does to system ASPs — the question is whether it stays contained to China.
Tariff & input costs
What breaks: roughly a point of gross margin. Already embedded in the 68–69% FY26 guide, plus higher freight and semiconductor costs flagged for the second half.
da Vinci 5 quality or recall event
What breaks: the upgrade cycle stalls. With ~half of U.S. dV5 placements being trade-ins, a field action would pause the single largest driver of system revenue.
FX & reimbursement timing
What breaks: reported growth optics. Ex-U.S. is now the faster half (+20%), so currency and country-level reimbursement decisions swing the headline more than they used to.
Leadership transition
What breaks: continuity of a famously long-horizon capital allocator — disruptive at the margin, but the installed base does not care who signs the letter.
The jargon, decoded
Hover the dotted terms anywhere in this report, or scan the desk's working definitions here.
- Installed base
- The number of systems already sitting in hospitals — 11,710 da Vinci and 1,096 Ion as of June 30, 2026. It matters because it generates revenue every time a surgeon uses it, with no new sale required.
- Recurring revenue
- Instruments, accessories and service — about 85% of Intuitive's total. It bills per procedure, which is why procedure growth, not system sales, is the number to watch.
- Razor-blade model
- Sell the handle cheap-ish, earn on the blades. Here the console is the razor and the $1.73B-a-quarter instruments line is the blades — and the blades are where the profit lives.
- Free cash flow (FCF)
- Cash left after running the business and paying for capital equipment. $3.22B trailing — the money that funds the buyback.
- FCF yield
- Free cash flow ÷ market cap. At 2.41%, the business throws off about $2.41 of cash a year per $100 of stock — thin, which is the value lens's core objection.
- EV/EBITDA
- Enterprise value (market cap plus debt, minus cash) divided by earnings before interest, tax, depreciation and amortization. 30.8× here. It strips out the balance sheet so companies with different cash piles compare fairly.
- PEG ratio
- The P/E divided by the earnings growth rate. 2.13 means you pay roughly two multiple points for each point of growth — above 2 is generally considered rich.
- Exit multiple
- The P/E assumed at the end of a forecast. Multiply projected EPS by it to get a target price. Every number in the scenario cards is built this way.
- GAAP vs. non-GAAP
- GAAP is the audited figure; non-GAAP strips out stock-based compensation and one-offs. For FY2025 the gap was $7.87 versus $8.93 per share — worth remembering when comparing multiples.
- de novo authorization
- The FDA pathway for a novel device with no existing equivalent to point at. J&J's Ottava took this route on July 22, 2026; Medtronic's Hugo came through the faster 510(k) route in December 2025.
- Trade-in placement
- A system sold to a hospital that already owns one, replacing it. Roughly half of U.S. da Vinci 5 placements — which is why record placement counts don't translate into equally fast installed-base growth.
- Probability-weighted
- Each scenario's price multiplied by its probability, then summed into a single expected value. The clay row in every scenario card, and the dotted line on the cone chart.